vs
Side-by-side financial comparison of TopBuild Corp (BLD) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.5B, roughly 1.6× TopBuild Corp). Zoetis runs the higher net margin — 25.3% vs 7.0%, a 18.2% gap on every dollar of revenue. On growth, TopBuild Corp posted the faster year-over-year revenue change (13.2% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $159.4M). Over the past eight quarters, TopBuild Corp's revenue compounded faster (7.8% CAGR vs 4.4%).
HashiCorp, Inc. is an American software company with a freemium business model based in San Francisco, California. HashiCorp provides tools and products that enable developers, operators and security professionals to provision, secure, run and connect cloud-computing infrastructure. It was founded in 2012 by Mitchell Hashimoto and Armon Dadgar. The company name HashiCorp is a portmanteau of co-founder last name Hashimoto and Corporation.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
BLD vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.4B |
| Net Profit | $104.5M | $603.0M |
| Gross Margin | 27.2% | 70.2% |
| Operating Margin | 12.1% | 31.9% |
| Net Margin | 7.0% | 25.3% |
| Revenue YoY | 13.2% | 3.0% |
| Net Profit YoY | -30.6% | 3.8% |
| EPS (diluted) | $3.69 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.2B | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.4B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.3B | $2.2B |
| Q4 25 | $104.5M | $603.0M | ||
| Q3 25 | $142.2M | $721.0M | ||
| Q2 25 | $151.6M | $718.0M | ||
| Q1 25 | $123.4M | $631.0M | ||
| Q4 24 | $150.5M | $581.0M | ||
| Q3 24 | $169.0M | $682.0M | ||
| Q2 24 | $150.7M | $624.0M | ||
| Q1 24 | $152.4M | $599.0M |
| Q4 25 | 27.2% | 70.2% | ||
| Q3 25 | 30.1% | 71.5% | ||
| Q2 25 | 30.4% | 73.6% | ||
| Q1 25 | 28.5% | 72.0% | ||
| Q4 24 | 29.9% | 69.5% | ||
| Q3 24 | 30.7% | 70.6% | ||
| Q2 24 | 31.0% | 71.7% | ||
| Q1 24 | 30.3% | 70.6% |
| Q4 25 | 12.1% | 31.9% | ||
| Q3 25 | 15.4% | 37.0% | ||
| Q2 25 | 16.9% | 36.7% | ||
| Q1 25 | 14.4% | 36.5% | ||
| Q4 24 | 16.6% | 31.6% | ||
| Q3 24 | 17.8% | 36.6% | ||
| Q2 24 | 15.4% | 33.0% | ||
| Q1 24 | 16.8% | 34.1% |
| Q4 25 | 7.0% | 25.3% | ||
| Q3 25 | 10.2% | 30.0% | ||
| Q2 25 | 11.7% | 29.2% | ||
| Q1 25 | 10.0% | 28.4% | ||
| Q4 24 | 11.5% | 25.1% | ||
| Q3 24 | 12.3% | 28.6% | ||
| Q2 24 | 11.0% | 26.4% | ||
| Q1 24 | 11.9% | 27.4% |
| Q4 25 | $3.69 | $1.37 | ||
| Q3 25 | $5.04 | $1.63 | ||
| Q2 25 | $5.32 | $1.61 | ||
| Q1 25 | $4.23 | $1.41 | ||
| Q4 24 | $5.07 | $1.29 | ||
| Q3 24 | $5.65 | $1.50 | ||
| Q2 24 | $4.78 | $1.37 | ||
| Q1 24 | $4.79 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.7M | — |
| Total DebtLower is stronger | $2.8B | — |
| Stockholders' EquityBook value | $2.3B | $3.3B |
| Total Assets | $6.6B | $15.5B |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $184.7M | — | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $842.5M | $1.4B | ||
| Q1 25 | $308.8M | $1.7B | ||
| Q4 24 | $400.3M | $2.0B | ||
| Q3 24 | $257.3M | $1.7B | ||
| Q2 24 | $463.2M | $1.6B | ||
| Q1 24 | $968.8M | $2.0B |
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $2.3B | $3.3B | ||
| Q3 25 | $2.2B | $5.4B | ||
| Q2 25 | $2.1B | $5.0B | ||
| Q1 25 | $2.1B | $4.7B | ||
| Q4 24 | $2.2B | $4.8B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $2.4B | $5.0B | ||
| Q1 24 | $2.7B | $5.1B |
| Q4 25 | $6.6B | $15.5B | ||
| Q3 25 | $6.4B | $15.2B | ||
| Q2 25 | $5.1B | $14.5B | ||
| Q1 25 | $4.6B | $14.1B | ||
| Q4 24 | $4.7B | $14.2B | ||
| Q3 24 | $4.7B | $14.4B | ||
| Q2 24 | $4.9B | $14.2B | ||
| Q1 24 | $5.3B | $14.3B |
| Q4 25 | 1.23× | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.52× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $176.7M | $893.0M |
| Free Cash FlowOCF − Capex | $159.4M | $732.0M |
| FCF MarginFCF / Revenue | 10.7% | 30.7% |
| Capex IntensityCapex / Revenue | 1.2% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.69× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $696.9M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $176.7M | $893.0M | ||
| Q3 25 | $233.3M | $938.0M | ||
| Q2 25 | $193.7M | $486.0M | ||
| Q1 25 | $152.6M | $587.0M | ||
| Q4 24 | $266.2M | $905.0M | ||
| Q3 24 | $240.7M | $951.0M | ||
| Q2 24 | $90.4M | $502.0M | ||
| Q1 24 | $178.8M | $595.0M |
| Q4 25 | $159.4M | $732.0M | ||
| Q3 25 | $216.2M | $805.0M | ||
| Q2 25 | $182.2M | $308.0M | ||
| Q1 25 | $139.2M | $438.0M | ||
| Q4 24 | $253.7M | $689.0M | ||
| Q3 24 | $219.8M | $784.0M | ||
| Q2 24 | $74.3M | $370.0M | ||
| Q1 24 | $158.9M | $455.0M |
| Q4 25 | 10.7% | 30.7% | ||
| Q3 25 | 15.5% | 33.5% | ||
| Q2 25 | 14.0% | 12.5% | ||
| Q1 25 | 11.3% | 19.7% | ||
| Q4 24 | 19.3% | 29.7% | ||
| Q3 24 | 16.0% | 32.8% | ||
| Q2 24 | 5.4% | 15.7% | ||
| Q1 24 | 12.4% | 20.8% |
| Q4 25 | 1.2% | 6.7% | ||
| Q3 25 | 1.2% | 5.5% | ||
| Q2 25 | 0.9% | 7.2% | ||
| Q1 25 | 1.1% | 6.7% | ||
| Q4 24 | 1.0% | 9.3% | ||
| Q3 24 | 1.5% | 7.0% | ||
| Q2 24 | 1.2% | 5.6% | ||
| Q1 24 | 1.6% | 6.4% |
| Q4 25 | 1.69× | 1.48× | ||
| Q3 25 | 1.64× | 1.30× | ||
| Q2 25 | 1.28× | 0.68× | ||
| Q1 25 | 1.24× | 0.93× | ||
| Q4 24 | 1.77× | 1.56× | ||
| Q3 24 | 1.42× | 1.39× | ||
| Q2 24 | 0.60× | 0.80× | ||
| Q1 24 | 1.17× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLD
| Distribution Segment | $755.4M | 51% |
| Residential | $557.9M | 38% |
| All Other Products | $91.9M | 6% |
| Glass And Windows | $51.5M | 3% |
| Rain Gutters | $27.1M | 2% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
